Trial
NCT01437605
Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
GlaxoSmithKline; Oncovir, Inc.
Condition
Melanoma
Intervention
MAGE-A3 ASCI injections without Poly IC:LC
Why stopped
Treatment Ineffective
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-12-20